Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse.

Slides:

Advertisements

Similar presentations

LTB4 production is elevated in preclinical and clinical lymphedema

Advertisements

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 4. Biomechanical properties of treated tibiae.

Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.

Fig. 4. Functional annotation of VUS in EGFR.

Fig. 1. Schematic representation of the MANO method.

Fig. 1. PARPi and MEKi induce inverse adaptive responses.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 3. A circadian rhythm in fibroblast wound-healing response.

MRSA virulence proteins cause LMC death and diminished CLV function

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Toxin production and release in vitro.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Fig. 6. A circadian rhythm in keratinocyte wound healing and a diurnal variation in human burn healing outcome. A circadian rhythm in keratinocyte wound.

Fig. 4. MATE1 transcription in RCC.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Fig. 4 Nanocages captured multiple TB-related analytes.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Fig. 1. Experimental workflow of the dAST method and computationally estimated operational space. Experimental workflow of the dAST method and computationally.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 2. Pathways differentially regulated in patients with early Lyme disease and STARI. Pathways differentially regulated in patients with early Lyme.

Fig. 2. Resistance to S63845-induced apoptosis through loss of BAK or elevated BCL-XL. Resistance to S63845-induced apoptosis through loss of BAK or elevated.

Workflow of a sample-to-answer AST performed in less than 30 min

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 3. ERRα is involved in the regulation of OPLAH.

Volume 18, Issue 11, Pages (November 2011)

Fig. 7 DMN-Tre labeling of Mycobacterium tuberculosis is inhibited by tuberculosis drug cocktail, unlike auramine staining. DMN-Tre labeling of Mycobacterium.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 1. Bexarotene promotes PPARδ activation to ameliorate the neurotoxicity of mutant huntingtin. Bexarotene promotes PPARδ activation to ameliorate the.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Fig. 1 Antibiotic-induced metabolome responses in M. smegmatis.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 5 DMN-Tre labeling is selective for live mycobacteria.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 8. Zbtb7a deficiency impairs antigen presentation by AMs.

Fig. 4. Induced Zbtb7a in lungs is localized to AMs.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 5 Putative latency-reversing agents exert differential effects on the different blocks to HIV transcription. Putative latency-reversing agents exert.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

BEZ235 induces accelerated senescence after radiation (IR) in vitro.

Presentation transcript:

Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. (A) Impact of Bio-AMS on viability of Mtb in standard liquid culture. The dashed line indicates the limit of detection. The frontline anti-TB drug isoniazid was used as a control. (B) Impact of Bio-AMS on growth of Mtb cultured on different carbon sources. Relative growth was calculated by dividing OD580 (optical density at 580 nm) of the culture treated with Bio-AMS by the OD580 of the culture in the absence of Bio-AMS. (C) Impact of Bio-AMS on intracellular Mtb in mouse macrophages. Mouse bone marrow–derived macrophages were infected with Mtb in vitro, and the culture was treated with Bio-AMS or dimethyl sulfoxide (DMSO) vehicle 24 hours after infection. Data are representative of two independent experiments each with three replicates and are means ± SEM (**P < 0.01, Student’s t test). Divya Tiwari et al., Sci Transl Med 2018;10:eaal1803 Published by AAAS